results of the latitude trial in high-risk metastatic hormone-naive prostate cancer
Published 7 years ago • 528 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
2:24
latitude study: major results in metastatic prostate cancer
-
2:04
results of a phase ii study of lhrh therapy in high-risk prostate cancer
-
1:17
dr. chi discusses the latitude study in metastatic prostate cancer
-
6:39
latitude supports first-line abiraterone use for metastatic prostate cancer | kim chi
-
1:44
dr. agarwal on the stampede and latitude trials for prostate cancer
-
2:06
dr. chi on androgen deprivation therapy for high-risk metastatic hormone-naive prostate cancer
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
10:00
results from acis trial of apalutamide abiraterone/prednisone in patients with chemo-naive mcrpc
-
1:27
dr. zhang discusses the impact of the stampede trial in prostate cancer
-
1:40
evaluating significance of enzamet trial in metastatic hormone-sensitive prostate cancer
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
2:14
latitude: phase iii final analysis
-
2:46
final analysis of latitude: abiraterone acetate prednisone added to adt
-
3:13
treatment options in metastatic prostate cancer
-
4:24
emuc18: stampede trial
-
1:38
5-year follow up of short-course abiraterone and adt for high-risk prostate cancer
-
6:48
docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer
-
4:44
prostate cancer update: practice-changing data?
-
19:51
metastatic prostate cancer - interpreting negative trial results